硫酸軟骨素蛋白聚糖4(CSPG4)活性蛋白
Active Chondroitin Sulfate Proteoglycan 4 (CSPG4)
CSPG4; MSK16; HMW-MAA; MCSP; MCSPG; MEL-CSPG; NG2; Chondroitin Sulfate Proteoglycan 4; Melanoma chondroitin sulfate proteoglycan
- 編號APB134Hu02
- 物種Homo sapiens (Human,人)相同的名稱,不同的物種。
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液(pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300)
- 性狀凍干粉
- 純度> 97%
- 等電點6.4
- 應用Cell?culture;?Activity?Assays.
- 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格¥ 1728¥ 4320¥ 8640¥ 25920¥ 64800
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
活性實驗

Figure. The binding activity of MCSP with GAL8.
Melanoma-associated chondroitin sulfate proteoglycan (MCSP) is a chondroitin sulfate proteoglycan in humans. CSPG4 plays a role in stabilizing cell-substratum interactions during early events of melanoma cell spreading on endothelial basement membranes. It represents an integral membrane chondroitin sulfate proteoglycan expressed by human malignant melanoma cells. Besides, Galectin-8 (GAL8) has been identified as an interactor of MCSP, thus a binding ELISA assay was conducted to detect the interaction of recombinant human MCSP and recombinant human GAL8. Briefly, MCSP were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to GAL8-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-MCSP pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of MCSP and GAL8 was shown in Figure 1, and this effect was in a dose dependent manner.

Figure. Western Blot
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當?shù)臈l件下存儲,損失率低于5%。
增值服務
相關(guān)產(chǎn)品
| 編號 | 適用物種:Homo sapiens (Human,人) | 應用(僅供研究使用,不用于臨床診斷!) |
| RPB134Hu02 | 硫酸軟骨素蛋白聚糖4(CSPG4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB134Hu01 | 硫酸軟骨素蛋白聚糖4(CSPG4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APB134Hu02 | 硫酸軟骨素蛋白聚糖4(CSPG4)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAB134Hu01 | 硫酸軟骨素蛋白聚糖4(CSPG4)多克隆抗體 | WB |
| PAB134Hu02 | 硫酸軟骨素蛋白聚糖4(CSPG4)多克隆抗體 | WB; IHC |
| LAB134Hu71 | 硫酸軟骨素蛋白聚糖4(CSPG4)多克隆抗體(生物素標記) | WB |
| MAB134Hu22 | 硫酸軟骨素蛋白聚糖4(CSPG4)單克隆抗體 | IHC |
| SEB134Hu | 硫酸軟骨素蛋白聚糖4(CSPG4)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB134Hu | 硫酸軟骨素蛋白聚糖4(CSPG4)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| The Effect of Denture Settling Period before Inserting Immediately Loaded Implants Used for Assisting Mandibular Complete Overdenture: Metabolic Activity of Peri-Implant Tissues[] |



